Cogent Biosciences, Inc.

Cogent Biosciences is a clinical-stage biotechnology company developing precision therapies targeting genetic mutations across multiple cancer and hematologic conditions. The company's lead candidate, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor currently in Phase 3 trials for systemic mastocytosis and advanced gastrointestinal stromal tumors, with development focused on mutations in the KIT receptor tyrosine kinase, particularly the KIT D816V mutation. The company operates under a licensing agreement with Plexxikon Inc. for bezuclastinib's research, development, and commercialization rights.

The pipeline additionally includes CGT4859, a Phase 1 fibroblast growth factor receptor 2 inhibitor for patients with FGFR mutations including advanced cholangiocarcinoma; CGT4255, an ErbB2 mutant-selective program targeting solid tumors and CNS-involved indications; and CGT6297, a PI3Ka mutant-selective inhibitor. These programs reflect the company's strategy of developing therapies for genetically defined patient populations with actionable mutations.

Cogent Biosciences is headquartered in Waltham, Massachusetts, and operates with approximately 258 full-time employees. As a clinical-stage company, the organization does not generate revenue from approved products. The company is incorporated in Delaware and trades on Nasdaq.